{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:05:08Z","timestamp":1780380308998,"version":"3.54.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Since the outbreak of the COVID-19 pandemic, extensive efforts including vaccine and drug development have been accentuated to address the emergence of SARS-CoV-2 variants. The rising variants and subvariants made early discoveries in effective treatment strategies less relevant and potent. For instance, multiple therapeutics like Evusheld are no longer effective against current variants and therefore have their emergency use authorizations (EUA), a regulatory mechanism allowing emergency use of medical products, revoked until further notice. Similarly, sotrovimab (STV), a human neutralizing monoclonal antibody (MAB), received EUA in May 2021 and was later granted authorization for COVID-19 treatment in Singapore. However, mutations presented in XBB, a subvariant of Omicron, substantially reduced the potency of STV at the currently approved dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To retain STV as a part of the treatment strategy for COVID-19 infected patients, it is important to carefully design and prioritize drugs that may further enhance the potency of STV when paired in combinations. In this study, IDentif.AI, an artificial intelligence (AI)-derived drug combination optimization platform, was harnessed to rapidly pinpoint STV-based combinations that may substantially improve the efficacy and potency of STV against XBB, which was predominantly spreading worldwide in 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IDentif.AI-pinpointed STV\/EIDD-1931 and STV\/GS-441524 combinations were able to interact synergistically to enhance efficacy against XBB and importantly, substantially reduce STV's in vitro EC50 (half maximal effective concentration) by up to 7-fold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This optimization platform represents a strategic approach to rapidly repurpose existing or previously failed therapeutics and subsequently restore their efficacy against a disease indication by pairing them with the correct drugs in combinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fdgth.2026.1744623","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:41:04Z","timestamp":1780378864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI"],"prefix":"10.3389","volume":"8","author":[{"given":"Peter","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"You","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Wei","family":"Chia","sequence":"additional","affiliation":[{"name":"National Centre for Infectious Diseases (NCID)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Hooi","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ming","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De Hoe","family":"Chye","sequence":"additional","affiliation":[{"name":"Defense Medical and Environmental Research Institute, DSO National Laboratories","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Moh","sequence":"additional","affiliation":[{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze Yong","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Lim","sequence":"additional","affiliation":[{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alrick Zi Xin","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaiah","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]},{"name":"Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Chang","sequence":"additional","affiliation":[{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Huan","family":"Tan","sequence":"additional","affiliation":[{"name":"Defense Medical and Environmental Research Institute, DSO National Laboratories","place":["Singapore, Singapore"]},{"name":"Repiratory and Infectious Disease Program, Lee Kong Chian School of Medicine, Nanyang Technological University","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys Gek Yen","family":"Tan","sequence":"additional","affiliation":[{"name":"Defense Medical and Environmental Research Institute, DSO National Laboratories","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Vasoo","sequence":"additional","affiliation":[{"name":"National Centre for Infectious Diseases (NCID)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad E. Z.","family":"Chan","sequence":"additional","affiliation":[{"name":"National Centre for Infectious Diseases (NCID)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Kai-Hua","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]},{"name":"Cancer Science Institute of Singapore, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore","place":["Singapore, Singapore"]},{"name":"Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The N.1 Institute for Health (N.1), National University of Singapore","place":["Singapore, Singapore"]},{"name":"Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"The Bia-Echo Asia Centre for Reproductive Longevity and Equality (ACRLE), National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1038\/s41598-024-54655-z","article-title":"AI Is a viable alternative to high throughput screening: a 318-target study","volume":"14","year":"2024","journal-title":"Sci Rep"},{"key":"B3","first-page":"4311","article-title":"Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry","volume-title":"Mol Pharm","author":"Zhavoronkov","year":"2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103772","DOI":"10.1016\/j.drudis.2023.103772","article-title":"Transforming drug discovery with a high-throughput AI-powered platform: a 5-year experience with patrimony","volume":"28","author":"de Th\u00e9","year":"2023","journal-title":"Drug Discov Today"},{"key":"B5","doi-asserted-by":"publisher","first-page":"eabg3338","DOI":"10.1126\/sciadv.abg3338","article-title":"Combining generative artificial intelligence and on-chip synthesis for de novo drug design","volume":"7","author":"Grisoni","year":"2021","journal-title":"Sci Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1073\/pnas.0800823105","article-title":"Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm","volume":"105","author":"Wong","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e15472","DOI":"10.1371\/journal.pone.0015472","article-title":"Statistical metamodeling for revealing synergistic antimicrobial interactions","volume":"5","author":"Chen","year":"2010","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-018-0069-9","article-title":"Prevalence and patterns of higher-order drug interactions in Escherichia coli","volume":"4","author":"Tekin","year":"2018","journal-title":"NPJ Syst Biol Appl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.isci.2021.102355","article-title":"Hidden suppressive interactions are common in higher-order drug combinations","volume":"24","author":"Lozano-Huntelman","year":"2021","journal-title":"Iscience"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e29074","DOI":"10.1002\/jmv.29074","article-title":"Neutralization escape of emerging subvariants XBB. 1.5\/1.9. 1 and XBB. 2.3 from current therapeutic monoclonal antibodies","volume":"95","author":"Chye","year":"2023","journal-title":"J Med Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1752-0509-5-88","article-title":"Systematic quantitative characterization of cellular responses induced by multiple signals","volume":"5","author":"Al-Shyoukh","year":"2011","journal-title":"BMC Syst Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2300332","DOI":"10.1002\/adtp.202300332","article-title":"Discovery of broad-spectrum repurposed drug combinations against carbapenem-resistant Enterobacteriaceae (CRE) through artificial intelligence (AI)-driven platform","volume":"7","author":"Li","year":"2024","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15141","DOI":"10.1021\/acsnano.2c06366","article-title":"IDentif. AI-omicron: harnessing an AI-derived and disease-agnostic platform to pinpoint combinatorial therapies for clinically actionable anti-SARS-CoV-2 intervention","volume":"16","author":"Blasiak","year":"2022","journal-title":"ACS Nano"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e10196","DOI":"10.1002\/btm2.10196","article-title":"IDentif. AI: rapidly optimizing combination therapy design against severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) with digital drug development","volume":"6","author":"Blasiak","year":"2021","journal-title":"Bioeng Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2000034","DOI":"10.1002\/adtp.202000034","article-title":"Project IDentif. AI: harnessing artificial intelligence to rapidly optimize combination therapy development for infectious disease intervention","volume":"3","author":"Abdulla","year":"2020","journal-title":"Adv Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.7150\/thno.73078","article-title":"Addressing antimicrobial resistance with the IDentif. AI platform: rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria","volume":"12","author":"Mukherjee","year":"2022","journal-title":"Theranostics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2200095","DOI":"10.1002\/aisy.202200095","article-title":"WisDM green: harnessing artificial intelligence to design and prioritize compound combinations in peat moss for sustainable farming applications","volume":"4","author":"Wang","year":"2022","journal-title":"Adv Intell Syst"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2402727","DOI":"10.1002\/adhm.202402727","article-title":"3D Bioprinting and artificial intelligence-assisted biofabrication of personalized oral soft tissue constructs","volume":"14","author":"Dai","year":"2024","journal-title":"Adv Healthcare Mater"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s44259-025-00079-2","article-title":"Flash optimization of drug combinations for Acinetobacter baumannii with IDentif. AI-AMR","volume":"3","author":"You","year":"2025","journal-title":"npj Antimicrob Resist"},{"key":"B20","doi-asserted-by":"publisher","first-page":"eaan0941","DOI":"10.1126\/scitranslmed.aan0941","article-title":"Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)","volume":"10","author":"Rashid","year":"2018","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1800104","DOI":"10.1002\/adtp.201800104","article-title":"Modulating BET bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform","volume":"1","author":"Pantuck","year":"2018","journal-title":"Adv Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41746-022-00627-4","article-title":"The IDentif. AI-x pandemic readiness platform: rapid prioritization of optimized COVID-19 combination therapy regimens","volume":"5","author":"Blasiak","year":"2022","journal-title":"npj Digit Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1900023","DOI":"10.1002\/adtp.201900023","article-title":"Harnessing CURATE. AI as a digital therapeutics platform by identifying N-of-1 learning trajectory profiles","volume":"2","author":"Kee","year":"2019","journal-title":"Adv Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-024-02653-3","article-title":"Radiation therapy with phenotypic medicine: towards N-of-1 personalization","volume":"131","author":"Chong","year":"2024","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2300236","DOI":"10.1002\/adtp.202300236","article-title":"CURATE. AI\u2014artificial intelligence-derived personalized tacrolimus dosing for pediatric liver transplant: a retrospective study","volume":"7","author":"Tan","year":"2024","journal-title":"Adv Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"eadu2695","DOI":"10.1126\/sciadv.adu2695","article-title":"Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform","volume":"11","author":"Vogt","year":"2025","journal-title":"Sci Adv"},{"key":"B27","year":"2021"},{"key":"B28","year":"2020"},{"key":"B29","year":"2018"},{"key":"B30","year":"2021"},{"key":"B31","year":"2021"},{"key":"B32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5705\/ss.2012.210","article-title":"Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration","volume":"24","author":"Xu","year":"2014","journal-title":"Stat Sin"},{"key":"B33","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"Synergyfinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B34","first-page":"49","article-title":"Uncertainty of measurement: a review of the rules for calculating uncertainty components through functional relationships","volume":"33","author":"Farrance","year":"2012","journal-title":"Clin Biochem Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screening"},{"key":"B36","year":"2024"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the parent nucleoside GS-441524 over remdesivir for COVID-19 treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.apsb.2021.03.028","article-title":"Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment","volume":"11","author":"Xie","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"B39","year":"2021"},{"key":"B40","year":"2020"},{"key":"B41","author":"Rubin","year":"2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41392-022-00963-7","article-title":"Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient\u2019s perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J Med Chem"},{"key":"B46","author":"Iversen","year":"2012"},{"key":"B47","year":"2024"},{"key":"B48","year":"2021"},{"key":"B49","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/v16020168","article-title":"In Vitro combinatorial activity of direct acting antivirals and monoclonal antibodies against the ancestral B. 1 and BQ. 1.1 SARS-CoV-2 viral variants","volume":"16","author":"Fiaschi","year":"2024","journal-title":"Viruses"},{"key":"B51","doi-asserted-by":"publisher","first-page":"103944","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMedicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.3390\/ijerph19084586","article-title":"Is the SARS CoV-2 omicron variant deadlier and more transmissible than delta variant?","volume":"19","author":"Duong","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41746-024-01195-5","article-title":"Personalized dose selection for the first waldenstr\u00f6m macroglobulinemia patient on the PRECISE CURATE. AI trial","volume":"7","author":"Blasiak","year":"2024","journal-title":"NPJ Digital Medicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1015355","DOI":"10.3389\/fimmu.2022.1015355","article-title":"Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1473-3099(23)00577-7","article-title":"Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study","volume":"24","author":"Fan","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"10231","DOI":"10.1073\/pnas.1612365113","article-title":"Pairwise interactions and the battle against combinatorics in multidrug therapies","volume":"113","author":"Wood","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-017-1818-2","article-title":"Predicting combinative drug pairs towards realistic screening via integrating heterogeneous features","volume":"18","author":"Shi","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","article-title":"Network-based prediction of drug combinations","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42490-024-00075-z","article-title":"Prediction of the synergistic effect of antimicrobial peptides and antimicrobial agents via supervised machine learning","volume":"6","author":"Olcay","year":"2024","journal-title":"BMC Biomed Eng"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1016\/S2666-5247(21)00216-0","article-title":"Estimating clinical SARS-CoV-2 infectiousness in vero E6 and primary airway epithelial cells","volume":"2","author":"Essaidi-Laziosi","year":"2021","journal-title":"Lancet Microbe"},{"key":"B61","author":"Rai","year":""},{"key":"B62","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.antiviral.2022.105429","article-title":"Generation of a VeroE6 pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study","volume":"208","author":"Zhu","year":"2022","journal-title":"Antiviral Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cpt.3337","article-title":"Pharmacokinetics, mass balance, safety, and tolerability of obeldesivir in healthy participants","volume":"116","author":"Anoshchenko","year":"2024","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1744623\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:41:06Z","timestamp":1780378866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1744623\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":63,"alternative-id":["10.3389\/fdgth.2026.1744623"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2026.1744623","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1744623"}}